1、1 2 Pankaj Manoria,P.C.Manoria.Indian Heart J 2007;59(3):2662723 Garber AJ.Am J Med 1997;102:491-74 Diabetes,Obesity and Metabolism,7,2005,28395 Diabetes,Obesity and Metabolism,7,2005,2839-3-3-2-2-5-5-8-8-9-9-8-8-7-7-6-6-5-5-4-4-3-3-2-2-1-10 0500mg500mg1000mg1000mg1500mg1500mg2000mg2000mg与安慰剂组比较的变化（
2、与安慰剂组比较的变化（mg/dlmg/dl）格华止缓释片剂量格华止缓释片剂量*p0.056 二甲双胍浓度(ng/ml)Acta diabetok lat.1988;25:55-62.,血清甘油三酯(mg/dl)7 Acta diabetok lat.1988;25:55-62.,二甲双胍浓度(ng/ml)血清高密度脂蛋白胆固醇(mg/dl)8 UKPDS 34.Lancet 1998;352:854-659 *P 0.05DIABETES,2006;55:496-505.10 Beisswenger PJ et al.Diabetes 1999;48:198-202二甲双胍二甲双胍2型糖尿病型
3、糖尿病甲基乙二醛浓度甲基乙二醛浓度(nmol/L)p=0.001p=NSp=0.026090120150180210无二甲双胍无二甲双胍1000 mg/天天11 Grant PJ.Diabetes Care 1996;19:64-612 Standeven KF et al.Diabetes 2002;51:189-97.13 14 4209(82%)17042505非超重组非超重组氯磺丙脲氯磺丙脲n=265胰岛素胰岛素n=409传统治疗传统治疗n=411二甲双胍强化治疗二甲双胍强化治疗n=342体重指数体重指数 25-30 46%体重指数体重指数 30 54%其它强化治疗其它强化治疗n=95
4、1格列本脲格列本脲n=409UK Prospective Diabetes Study(UKPDS)Group.Lancet.Lancet 1998;352:854-65.15 UK Prospective Diabetes Study(UKPDS)Group.Lancet.Lancet 1998;352:854-65.16 UK Prospective Diabetes Study(UKPDS)Group.Lancet.Lancet 1998;352:854-65.020406003691216M vs.C：p=0.0023M vs.I：p=0.003417 UK Prospective D
5、iabetes Study(UKPDS)Group.Lancet.Lancet 1998;352:854-65.18 19 格华止剂量格华止剂量(mg/day)患者患者(%)副作用发生频率副作用发生频率因副作用停药率因副作用停药率Garber AJ.Am J Med 1997;102:491-720 0 010102020303040405050606070708080909010010050050010001000150015002000200025002500剂量剂量(mg)(mg)FPGFPG安慰剂比较的下降值安慰剂比较的下降值(mg/dl)(mg/dl)胃胃肠肠道道反反应应发发生生率率最佳剂量最佳剂量Garber AJ.Am J Med 1997;102:491-721 22 23 24写在最后写在最后成功的基础在于好的学习习惯成功的基础在于好的学习习惯The foundation of success lies in good habits谢谢大家荣幸这一路，与你同行ItS An Honor To Walk With You All The Way讲师：XXXXXX XX年XX月XX日
